Fingerprint
Dive into the research topics of 'Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically